Mineralys Therapeutics (MLYS) Payables (2022 - 2026)

Mineralys Therapeutics has reported Payables for 5 years, with the latest figure at $1.1 million in Q1 2026.

• Quarterly Payables rose 199.2% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 199.2% YoY) and the FY2025 annual result came in at $2.0 million, up 321.09% from the prior year.
• Payables fell to $1.1 million in Q1 2026 per MLYS's latest filing, from $2.0 million in the prior quarter.
• Over five years, Payables peaked at $5.6 million in Q3 2023 and troughed at $373000.0 in Q1 2025.
• A 5-year average of $2.1 million and a median of $2.0 million in 2022 frame the typical range for Payables.
• The widest YoY moves for Payables: up 321.09% in 2025, down 91.25% in 2025.
• Over 5 years, Payables stood at $1.9 million in 2022, then sank by 68.48% to $601000.0 in 2023, then retreated by 20.3% to $479000.0 in 2024, then soared by 321.09% to $2.0 million in 2025, then plunged by 44.67% to $1.1 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $1.1 million, $2.0 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.